Sildenafil is cleared predominantly through metabolism rather than excretion of unchanged parent drug. Current U.S. labeling identifies CYP3A4 as the major metabolic route and CYP2C9 as a minor route, with hepatic biotransformation contributing both to first-pass loss after oral administration and to later systemic clearance.
The best-characterized circulating product is N-desmethyl sildenafil, formed through N-demethylation of the parent drug. Human metabolism studies also identify additional pathways including pyrazole N-demethylation, N,N′-deethylation, piperazine-ring oxidation and aliphatic hydroxylation.
This page maps those metabolic processes from parent sildenafil through active and downstream metabolites to eventual excretion. Detailed CYP3A4 interaction effects remain on the sildenafil CYP3A4 page, while the pharmacology of N-desmethyl sildenafil is covered on the sildenafil active metabolite page.
Sildenafil metabolism is the enzyme-mediated chemical transformation of unchanged parent sildenafil into related metabolites. It is one of the principal processes responsible for removing parent sildenafil from the circulating drug pool.
Metabolism is not limited to one event after distribution has finished. Presystemic metabolism contributes before the full oral dose reaches systemic circulation, and metabolic transformation continues after sildenafil has entered the systemic circulation.
Metabolism should also be separated from excretion. Metabolism changes the chemical identity of the drug, whereas excretion is the later removal of sildenafil-related material from the body. Within the broader sildenafil pharmacokinetic framework, the two processes are connected but not synonymous.
| Concept | Sildenafil-Specific Meaning |
|---|---|
| Parent sildenafil | Unchanged pharmacologically active drug before metabolic transformation |
| Metabolism | Enzyme-mediated conversion of parent sildenafil into metabolites |
| Metabolite | Chemical product formed from parent sildenafil |
| Excretion | Removal of drug-related material from the body |
| Clearance | Overall efficiency with which parent drug is removed from the relevant systemic compartment |
The liver is the principal established site of sildenafil metabolism. Current labeling describes sildenafil clearance through hepatic microsomal CYP3A4 and CYP2C9 pathways.
Metabolism is relevant both before and after sildenafil reaches the general circulation. Human pharmacokinetic studies show that oral sildenafil is rapidly absorbed but undergoes substantial presystemic metabolism, which reduces the fraction of unchanged drug reaching systemic circulation.
After systemic exposure has been established, circulating sildenafil continues to undergo hepatic metabolic clearance. The same broad enzyme system therefore contributes to both first-pass disposition and subsequent removal of parent drug.
| Metabolic Context | Sildenafil PK Significance |
|---|---|
| Presystemic hepatic metabolism | Reduces the amount of orally absorbed sildenafil reaching systemic circulation unchanged |
| Systemic hepatic metabolism | Removes circulating parent sildenafil through biotransformation |
| Metabolite formation | Creates active and downstream sildenafil-related products |
| Further metabolism | Transforms primary metabolites into additional products before excretion |
Current U.S. labeling identifies CYP3A4 as the major route of sildenafil metabolism and CYP2C9 as a minor route. These hepatic cytochrome P450 enzymes contribute to oxidative transformation of the parent drug.
Human liver-microsome and recombinant-enzyme studies support that hierarchy. Experimental work examining N-demethylation estimated that at least about three quarters of this pathway across the tested concentration range was attributable to CYP3A4, with CYP2C9 making a smaller contribution.
Other CYP enzymes have shown small activity in some in-vitro systems, but current clinical labeling emphasizes CYP3A4 and CYP2C9. Detailed interaction consequences of inhibiting or inducing the major pathway remain on the sildenafil CYP3A4 guide.
| Enzyme Pathway | Role in Sildenafil Metabolism |
|---|---|
| CYP3A4 | Major labeled metabolic pathway |
| CYP2C9 | Minor labeled metabolic pathway |
| CYP3A4 in N-demethylation studies | Estimated to account for at least about 75% of N-demethylation across tested in-vitro conditions |
| Other CYP activity | Minor in-vitro contributions have been reported but are not the principal pathways emphasized in labeling |
Sildenafil metabolism is not a single one-step reaction. Human metabolic profiling has identified several pathways that modify different parts of the sildenafil molecule.
The principal reported pathways include piperazine N-demethylation, pyrazole N-demethylation, N,N′-deethylation involving loss of a two-carbon fragment from the piperazine ring, oxidation of the piperazine ring and aliphatic hydroxylation.
Additional metabolites can arise when these reactions occur sequentially or in combination. The result is a metabolic network in which parent sildenafil is progressively converted into several drug-related products rather than directly transformed into one final inactive compound.
| Metabolic Pathway | General Result |
|---|---|
| Piperazine N-demethylation | Produces the major circulating N-desmethyl metabolite |
| Pyrazole N-demethylation | Removes a methyl group at a different site of the molecule |
| N,N′-deethylation | Removes a two-carbon fragment from the piperazine-related structure |
| Piperazine-ring oxidation | Oxidative transformation of the piperazine portion |
| Aliphatic hydroxylation | Adds a hydroxyl group through oxidative metabolism |
| Combined downstream reactions | Generate additional secondary metabolites |
The major circulating active metabolite is N-desmethyl sildenafil, formed through N-demethylation of the parent drug. It remains pharmacologically active rather than representing an immediately inactive end product.
Current labeling reports that the metabolite has a PDE selectivity profile similar to sildenafil and an in-vitro PDE5 potency of approximately 50% of the parent compound. In healthy volunteers, its plasma concentrations are approximately 40% of parent sildenafil concentrations.
Labeling estimates that this exposure and potency combination accounts for about 20% of sildenafil's overall pharmacological effects. The metabolite is itself further metabolized and has a terminal half-life of about 4 hours. Detailed interpretation remains on the sildenafil active metabolite page.
| Active-Metabolite Feature | Current Label Context |
|---|---|
| Metabolite | N-desmethyl sildenafil |
| Formation | N-demethylation of parent sildenafil |
| Relative in-vitro PDE5 potency | Approximately 50% of parent sildenafil |
| Healthy-volunteer plasma concentration | Approximately 40% of parent sildenafil |
| Estimated pharmacologic contribution | Approximately 20% |
| Terminal half-life | About 4 hours |
Metabolic clearance is a major determinant of parent sildenafil exposure. When CYP-mediated metabolic capacity decreases, unchanged sildenafil can remain at higher concentrations and produce greater integrated systemic exposure.
The opposite direction is also possible. Increased metabolic capacity through enzyme induction can reduce parent sildenafil exposure by accelerating metabolic removal.
This relationship explains why CYP3A inhibitors and inducers can materially alter sildenafil pharmacokinetics, but detailed interaction magnitudes belong on the sildenafil CYP3A4 page and sildenafil drug interactions page. The broader exposure framework remains on the sildenafil exposure page.
| Metabolic Change | Expected Parent-Drug Direction |
|---|---|
| Reduced CYP-mediated metabolism | Higher sildenafil exposure |
| Increased CYP-mediated metabolism | Lower sildenafil exposure |
| Reduced apparent oral clearance | Can increase parent-drug AUC |
| Altered metabolite formation | Can change the parent-to-metabolite exposure relationship |
AUC measures integrated sildenafil concentration over time, while metabolism is one of the processes that helps determine that exposure. The two should therefore be related without being treated as interchangeable.
For an orally administered drug, parent sildenafil AUC depends on both systemic input and clearance. Presystemic metabolism can reduce the amount of unchanged drug reaching circulation, while systemic metabolism contributes to the subsequent removal of parent sildenafil.
This is one reason sildenafil's absolute oral bioavailability is substantially below complete systemic availability even though gastrointestinal absorption itself is high. The exposure metric is treated on the sildenafil AUC page, while absolute availability is covered on the sildenafil bioavailability page.
| Concept | Relationship to Metabolism |
|---|---|
| Presystemic metabolism | Can reduce unchanged sildenafil input into systemic circulation |
| Systemic metabolism | Contributes to removal after sildenafil reaches circulation |
| AUC | Integrated result of systemic input and removal |
| Absolute bioavailability | Reflects systemic availability after absorption and presystemic loss |
Metabolism describes chemical transformation, while clearance describes the efficiency with which parent sildenafil is removed from a defined systemic compartment. Metabolism is a mechanism that contributes strongly to sildenafil clearance but is not itself the clearance parameter.
Radiolabeled human studies reinforce the importance of metabolism: unchanged sildenafil was not detected in human urine or feces after the studied oral and intravenous administrations. Parent drug had been transformed before the drug-related material was excreted.
That observation does not mean excretion is unimportant. It means that excreted sildenafil-related material consists predominantly of metabolites rather than unchanged parent sildenafil. Quantitative systemic removal is covered on the sildenafil clearance page.
| Feature | Metabolism | Clearance |
|---|---|---|
| Primary meaning | Chemical transformation of sildenafil | Efficiency of parent-drug removal |
| Describes enzymes? | Yes | Not directly |
| Major sildenafil mechanism? | Yes; CYP-mediated metabolism is central | Metabolic processes contribute strongly to overall removal |
| Unchanged drug in human excreta in radiolabel study | Not detected | Supports metabolism as the dominant parent-drug removal mechanism |
| Same concept? | No | No |
Metabolism changes sildenafil into chemically different products, while elimination is the broader sequence through which sildenafil-related material ultimately leaves the body.
Current U.S. labeling reports that after oral or intravenous sildenafil administration, drug-related material is excreted as metabolites predominantly in feces, accounting for approximately 80% of the administered oral dose, and to a lesser extent in urine, accounting for approximately 13%.
The sequence can therefore be summarized as parent sildenafil undergoing metabolic transformation, metabolites undergoing additional disposition or further metabolism, and sildenafil-related material eventually being excreted. Parent-drug disappearance from plasma is not the same event as complete elimination of all drug-related material.
| Process | Sildenafil-Specific Outcome |
|---|---|
| Metabolism | Parent sildenafil is converted into N-desmethyl and other metabolites |
| Further metabolism | Primary metabolites can undergo additional transformations |
| Fecal excretion | Approximately 80% of administered oral dose as metabolites |
| Urinary excretion | Approximately 13% of administered oral dose as metabolites |
| Unchanged sildenafil in human excreta | Not detected in the referenced radiolabeled metabolism study |
Sildenafil metabolic capacity is not identical in every pharmacokinetic context. Enzyme inhibition, enzyme induction, hepatic function and interindividual enzyme activity can all alter parent-drug and metabolite exposure.
CYP3A4 is particularly important because clinically used inhibitors can reduce sildenafil metabolism substantially, while CYP3A induction can move exposure in the opposite direction. These interaction effects are large enough to be addressed explicitly in product labeling.
Genetic and physiological variation in CYP activity has also been investigated, but in-vitro genotype findings should not automatically be converted into individual clinical predictions. Broader variability remains on the sildenafil PK variability page.
| Source of Variation | Potential Metabolic Effect |
|---|---|
| CYP3A inhibition | Reduced parent-drug metabolism and increased exposure |
| CYP induction | Increased metabolic capacity and lower parent-drug exposure |
| Hepatic impairment | Reduced clearance and higher exposure in studied populations |
| Interindividual CYP activity | Can contribute to differences in metabolic rate |
| Metabolite disposition | Can alter the observed parent-to-metabolite profile |
The importance of hepatic metabolism is demonstrated directly by sildenafil studies in liver impairment. Reduced hepatic function can decrease sildenafil clearance and increase parent-drug systemic exposure.
Current labeling reports that in Child-Pugh A and B hepatic impairment, sildenafil clearance was reduced, with AUC approximately 85% higher and Cmax approximately 47% higher than in age-matched subjects without hepatic impairment.
Those findings demonstrate altered disposition but do not prove that every metabolic pathway changes by the same proportion. Severe Child-Pugh C impairment has not been adequately characterized in the relevant PK dataset. Detailed population analysis remains on the sildenafil hepatic impairment pharmacokinetics page.
| Hepatic Context | Observed Sildenafil Finding |
|---|---|
| Child-Pugh A/B | Reduced sildenafil clearance |
| Parent sildenafil AUC | Approximately 85% higher |
| Parent sildenafil Cmax | Approximately 47% higher |
| Child-Pugh C | Not adequately studied in the current PK evidence base |
| Detailed analysis | Sildenafil PK in Hepatic Impairment |
Metabolic clearance contributes to the decline of parent sildenafil concentrations, so metabolism is one determinant of the observed elimination time scale.
Current labeling reports terminal half-lives of about 4 hours for both parent sildenafil and its major active N-desmethyl metabolite. That similarity does not mean that the two analytes have identical formation and elimination pathways.
Half-life cannot be calculated from enzyme identity alone because terminal decline also reflects distribution and the complete elimination system. The parameter itself is covered on the sildenafil half-life page.
| Concept | Sildenafil Context |
|---|---|
| Parent metabolism | Contributes to removal of unchanged sildenafil |
| Parent terminal half-life | About 4 hours |
| N-desmethyl metabolite terminal half-life | About 4 hours |
| Distribution | Also contributes to the observed terminal decline |
| Metabolism alone determines half-life? | No |
Sildenafil metabolism has been studied using complementary approaches because no single experiment describes the entire pathway. Human liver microsomes and recombinant CYP systems help identify the enzymes responsible for specific transformations such as N-demethylation.
Radiolabeled human studies allow investigators to follow total sildenafil-related material through plasma, urine and feces and to distinguish unchanged parent drug from individual metabolites.
Serial plasma sampling and metabolite profiling then show how parent sildenafil and major metabolic products change over time. Together these methods establish both the enzyme-level pathway and the whole-body disposition of sildenafil-related material.
| Research Approach | What It Helps Characterize |
|---|---|
| Human liver microsomes | Overall hepatic metabolic activity and enzyme inhibition |
| Recombinant CYP enzymes | Contribution of specific CYP pathways |
| Radiolabeled sildenafil | Whole-body recovery of parent drug and metabolites |
| Plasma metabolite profiling | Relative circulating parent and metabolite exposure |
| Urine and feces profiling | Routes and chemical form of excreted drug-related material |
Sildenafil metabolism links absorption and systemic exposure to clearance and eventual excretion. Presystemic metabolism reduces unchanged oral systemic input, while systemic CYP-mediated metabolism progressively removes circulating parent sildenafil.
The resulting metabolites then have their own concentration-time profiles. N-desmethyl sildenafil remains pharmacologically active, while additional downstream transformations move drug-related material toward elimination.
Metabolism therefore explains an important part of sildenafil disposition without replacing neighboring PK concepts. For the full ADME sequence, the sildenafil pharmacokinetics hub connects metabolism with absorption, bioavailability, distribution, exposure, clearance and half-life.
| Research Question | Most Relevant Topic |
|---|---|
| How does sildenafil enter systemic circulation? | Sildenafil Absorption |
| How much reaches systemic circulation unchanged? | Sildenafil Bioavailability |
| How does it move between plasma and tissues? | Sildenafil Distribution |
| How is parent sildenafil chemically transformed? | Sildenafil metabolism — this page |
| Which major enzyme pathway is involved? | Sildenafil and CYP3A4 |
| What active metabolic product is formed? | Sildenafil Active Metabolite |
| How efficiently is parent drug removed? | Sildenafil Clearance |
| What is the terminal decline time scale? | Sildenafil Half-Life |
Sildenafil is metabolized predominantly through hepatic CYP pathways. CYP3A4 is the major route and CYP2C9 is a minor route. Metabolism includes N-demethylation and several additional oxidative transformations.
Human metabolism studies have identified piperazine N-demethylation, pyrazole N-demethylation, N,N′-deethylation, piperazine-ring oxidation and aliphatic hydroxylation, with additional metabolites formed through combinations of these reactions.
The major circulating active metabolite is N-desmethyl sildenafil. Current labeling reports approximately half the parent's in-vitro PDE5 potency and plasma concentrations around 40% of parent sildenafil in healthy volunteers.
Metabolism is the dominant route of parent-drug removal. In a radiolabeled human study, unchanged sildenafil was not detected in urine or feces; drug-related material was recovered predominantly as metabolites.
Current labeling states that sildenafil is excreted as metabolites predominantly in feces, representing approximately 80% of the administered oral dose, and to a lesser extent in urine, representing approximately 13%.
No. Metabolism is the chemical transformation of sildenafil, while clearance describes the efficiency of parent-drug removal from circulation. CYP-mediated metabolism is an important mechanism contributing to sildenafil clearance.